Aclaris Therapeutics, Inc. (ACRS) vs Climb Bio, Inc. (CLYM)
A side-by-side comparison of Aclaris Therapeutics, Inc. and Climb Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$3.97HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
CLYM
Climb Bio, Inc.
$11.13HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — ACRS vs CLYM
growth of $100 · dividends reinvested · last 2yACRS +265.0% (+91.0%/yr)CLYM +41.1% (+18.8%/yr)ACRS compounded faster over this window
ACRS CLYM
ACRS vs CLYM: by the numbers
- •CLYM is the larger company ($637M vs $554M market cap).
- •Both run net losses; CLYM's is the smaller (0.00% vs -921.50% net margin).
Metrics side by side
Valuation
| Metric | ACRS | CLYM |
|---|---|---|
| P/S ratio | 67.46 | N/A |
| P/B ratio | 4.45 | 2.66 |
Profitability
| Metric | ACRS | CLYM |
|---|---|---|
| Gross margin | 73.28% | 0.00% |
| Operating margin | -975.91% | 0.00% |
| Net margin | -921.50% | 0.00% |
| ROE | -60.79% | -24.06% |
| ROIC | -56.99% | -26.94% |
Growth (annualized)
| Metric | ACRS | CLYM |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | N/A |
| Total return CAGR (5Y) | -24.23% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.